Ex Parte Mazur - Page 3


             Appeal No.  2004-0394                                                        Page 3                     
             Application No.   09/915,467                                                                            
                                                   DISCUSSION                                                        
                    According to appellant (Request, page 2), “[i]t is undisputed that the prior art                 
             acknowledges a long-felt need for the problem of teratogen-related birth defects.”                      
             Nevertheless, appellant asserts (Request, page 3), “[d]espite a panoply of proposed                     
             solutions, as recently as 2001 the art had failed to solve this problem.  This failure to               
             solve the long-felt need is shown both by [pregnancy] data collected by the                             
             manufacturer of ACCUTANEŽ isotretinoin, and by the United States Food & Drug                            
             Administration’s interpretation of this data.”  According to appellant (Request, page 4),               
             “[t]he reason for these pregnancies, despite ostensibly clear admonitions to avoid                      
             pregnancy, is unclear.”  However, appellant notes that Woodcock (Appendix to Brief)                     
             asserts “exclusive reliance on ‘human memory’ is not an adequate precaution for                         
             managing severe risks.”  Id.  According to appellant (id.),                                             
                    The Food & Drug Administration thus concluded that “additional                                   
                    systematized measures to manage risk and fully inform patients and                               
                    families should be instituted, given the devastating impact of potential side                    
                    effects.” …  Notably, the FDA advanced this position in 2001 – clearly                           
                    showing that the long-felt need remained unsatisfied at that time.”                              
                    Accordingly, appellant asserts (Request, bridging paragraph, pages 4-5,                          
             footnotes omitted), since Abrams, Elsayed and PDR “were followed temporally by …                        
             WOODCOCK … and by Roche Pharmaceuticals, Inc., APPENDIX I … the long-felt need                          
             remained unfulfilled as recently as several months before Appellant filed the immediate                 
             application.”  In support of this assertion appellant states (Request, page 5, fn. 5):                  
                    Notably, ABRAMS, ELSAYED, and THE PHYSICIANS DESK REFERENCE each                                 
                    preceded ROCHE PHARMACEUTICALS, INC., APPENDIX I (2001), and thus by                             
                    definition lacked knowledge of the data presented there.  Thus, an earlier                       
                    allegation of solving the long-felt need (if such an allegation in fact were                     
                    shown in the record) would appear baseless, directly contradicted by the                         
                    subsequent 2001 data, and thus unsustainable as a matter of law.                                 
             I.  Appellant’s implied satisfaction of a long-felt need unsupported by evidence:                       





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  Next 

Last modified: November 3, 2007